Literature DB >> 16868453

Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients.

Blai Coll1, Gerard Aragonés, Sandra Parra, Carlos Alonso-Villaverde, Lluis Masana.   

Abstract

We tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16868453     DOI： 10.1097/01.aids.0000238418.43937.3b

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  17 in total

Review 1.  Dyslipidemia and its Treatment in HIV Infection.

Authors:  Carl Grunfeld
Journal:  Top HIV Med       Date:  2010 Aug-Sep

Review 2.  Lipodystrophy: pathophysiology and advances in treatment.

Authors:  Christina G Fiorenza; Sharon H Chou; Christos S Mantzoros
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

3.  Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.

Authors:  S Oswald; H E Meyer zu Schwabedissen; A Nassif; C Modess; Z Desta; E T Ogburn; J Mostertz; M Keiser; J Jia; A Hubeny; A Ulrich; D Runge; M Marinova; D Lütjohann; H K Kroemer; W Siegmund
Journal:  Clin Pharmacol Ther       Date:  2012-02-01       Impact factor: 6.875

Review 4.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

Review 5.  Dyslipidemia and lipid management in HIV-infected patients.

Authors:  Janet Lo
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-04       Impact factor: 3.243

Review 6.  Treatment of dyslipidemia in HIV.

Authors:  Rajagopal V Sekhar
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

7.  Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients.

Authors:  Dominic Chow; Huichao Chen; Marshall J Glesby; Anthony Busti; Scott Souza; Janet Andersen; Sharon Kohrs; Julia Wu; Susan L Koletar
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

8.  Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.

Authors:  David A Wohl; David Waters; Ross J Simpson; Susan Richard; Amanda Schnell; Sonia Napravnik; Jessica Keys; J Joseph Eron; Priscilla Hsue
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

Review 9.  Approach to the human immunodeficiency virus-infected patient with lipodystrophy.

Authors:  Todd T Brown
Journal:  J Clin Endocrinol Metab       Date:  2008-08       Impact factor: 5.958

10.  New options in the treatment of lipid disorders in HIV-infected patients.

Authors:  Erika Ferrari Rafael da Silva; Giuseppe Bárbaro
Journal:  Open AIDS J       Date:  2009-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.